SELLAS Life Sciences Group, Inc. $SLS Stock Position Increased by Dagco Inc.

Dagco Inc. increased its position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) by 78.1% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,028,780 shares of the company’s stock after buying an additional 451,240 shares during the quarter. SELLAS Life Sciences Group comprises approximately 0.9% of Dagco Inc.’s holdings, making the stock its 23rd largest position. Dagco Inc. owned approximately 0.57% of SELLAS Life Sciences Group worth $4,352,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of SLS. Anson Funds Management LP raised its position in SELLAS Life Sciences Group by 2,093.8% in the third quarter. Anson Funds Management LP now owns 6,032,938 shares of the company’s stock worth $9,713,000 after acquiring an additional 5,757,938 shares in the last quarter. Everhart Financial Group Inc. boosted its position in shares of SELLAS Life Sciences Group by 40.8% during the 4th quarter. Everhart Financial Group Inc. now owns 466,216 shares of the company’s stock valued at $1,758,000 after purchasing an additional 135,066 shares in the last quarter. Trustmark Bank Trust Department acquired a new position in shares of SELLAS Life Sciences Group in the 3rd quarter worth approximately $59,000. Money Concepts Capital Corp acquired a new position in shares of SELLAS Life Sciences Group in the 4th quarter worth approximately $40,000. Finally, CWM LLC raised its holdings in shares of SELLAS Life Sciences Group by 124.7% in the 4th quarter. CWM LLC now owns 11,782 shares of the company’s stock worth $44,000 after purchasing an additional 6,538 shares in the last quarter. Institutional investors own 17.38% of the company’s stock.

SELLAS Life Sciences Group Trading Up 14.8%

SLS stock opened at $10.53 on Friday. SELLAS Life Sciences Group, Inc. has a one year low of $1.39 and a one year high of $11.06. The firm has a 50-day moving average of $6.99 and a two-hundred day moving average of $5.10. The firm has a market capitalization of $2.07 billion, a PE ratio of -45.78 and a beta of 2.50.

SELLAS Life Sciences Group (NASDAQ:SLS) last released its earnings results on Tuesday, May 12th. The company reported ($0.05) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.01.

Analyst Upgrades and Downgrades

A number of brokerages recently weighed in on SLS. Weiss Ratings restated a “sell (d-)” rating on shares of SELLAS Life Sciences Group in a report on Tuesday, April 21st. Maxim Group increased their price objective on SELLAS Life Sciences Group from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Thursday, March 12th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $10.00.

SELLAS Life Sciences Group Profile

SELLAS Life Sciences Group, Inc is a clinical-stage biopharmaceutical company focused on the development of active cellular immunotherapies for cancer. Headquartered in Waltham, Massachusetts, SELLAS specializes in targeting the Wilms’ tumor 1 (WT1) antigen, a protein commonly overexpressed in a range of hematologic and solid tumors. Since its founding, the company has built a pipeline around the use of peptide-based vaccines designed to train the patient’s own immune system to recognize and attack WT1-positive cancer cells.

The company’s lead product candidate, galinpepimut-S (GPS), is an investigational multi-peptide vaccine directed against WT1.